Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 12, 2025Journal of Pharmacy & Pharmacognosy ResearchOpen Access

Predicting activities of Clinacanthus nutans (Burm.f.) Lindau metabolites against molecular targets in metabolic dysfunction-associated steatotic liver disease

View Full Paper
Ask AI
Bookmark
Share

Authors

NHNurina HasanatuludhhiyahAMArifa MustikaVKViskasari Pintoko Kalanjati

Discussion

Loading...

Member takes

Overview

In silico analyses predict multi-target interactions of Clinacanthus nutans compounds in MASLD, suggesting therapeutic potential.

Key Points

  • Six metabolites from Clinacanthus nutans showed favorable pharmacokinetic properties, indicating their potential as therapeutic agents.
  • Molecular docking revealed strong binding affinities of a thiophene-based derivative and tagalsin Q toward CCR2, ChREBP, and SGLT2.
  • Seventeen compounds were identified through metabolite profiling using ultra-high-performance liquid chromatography–mass spectrometry.
  • ADMET profiling confirmed that the selected compounds from C. nutans met drug-likeness criteria essential for further development.

Cite This Study

Hasanatuludhhiyah et al. (2025) studied this question.

synapsesocial.com/papers/68d44a3031b076d99fa53222https://doi.org/10.56499/jppres24.2246_13.s1.316
View Full Paper
Ask AI
Bookmark
Share